{
    "status": "ok",
    "totalResults": 9,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15",
            "description": "(marketscreener.com) \n35-subject SWING Trial evaluates the safety, performance of Surmodics\u2019 Sundance\u2122 Sirolimus Drug-Coated Balloon\n\n\nUpdated safety and performance data for the SWING trial 24-month data will be shared\n\nhttps://www.marketscreener.com/quote/s\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodics-Announces-SWING-Trial-24-Month-Data-to-be-Presented-at-VEITH-Symposium-on-November-15-45259609/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-07T12:32:02Z",
            "content": "35-subject SWING Trial evaluates the safety, performance of Surmodics Sundance Sirolimus Drug-Coated Balloon\r\nUpdated safety and performance data for the SWING trial 24-month data will be shared\r\nSur\u2026 [+4916 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Surmodics : Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance - Form 8-K",
            "description": "(marketscreener.com) and ultimately exceeded our guidance range, driven by impressive contributions from both of our business segments,\" said Gary Maharaj, President and CEO of Surmodics, Inc. \"We complemented our fourth quarter revenue performance with notab\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodics-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results-Introduces-Fiscal-Year-20-45271386/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-08T12:03:08Z",
            "content": "Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results;\r\nIntroduces Fiscal Year 2024 Financial Guidance\r\nNovember 8, 2023 07:00 a.m. ET\r\nEDEN PRAIRIE, Minn. - Surmodics, Inc. (Nasdaq\u2026 [+46034 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Surmodics (NASDAQ:SRDX) Price Target Increased to $71.00 by Analysts at Barrington Research",
            "description": "Surmodics (NASDAQ:SRDX \u2013 Free Report) had its price target increased by Barrington Research from $69.00 to $71.00 in a research report released on Thursday, Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other researc\u2026",
            "url": "https://www.etfdailynews.com/2023/11/10/surmodics-nasdaqsrdx-price-target-increased-to-71-00-by-analysts-at-barrington-research/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/surmodics-inc-logo.png?v=20221209141149&w=240&h=240&zc=2",
            "publishedAt": "2023-11-10T13:16:51Z",
            "content": "Surmodics (NASDAQ:SRDX \u2013 Free Report) had its price target increased by Barrington Research from $69.00 to $71.00 in a research report released on Thursday, Benzinga reports. The brokerage currently \u2026 [+2890 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium",
            "description": "(marketscreener.com) \nSurmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the \u2026",
            "url": "https://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodics-Announces-TRANSCEND-Trial-36-Month-Data-Presented-at-50th-Annual-VEITH-Symposium-45373086/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-16T12:32:02Z",
            "content": "Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical tr\u2026 [+6060 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Surmodics (NASDAQ:SRDX) Price Target Cut to $44.00 by Analysts at Needham & Company LLC",
            "description": "Surmodics (NASDAQ:SRDX \u2013 Free Report) had its price objective reduced by Needham & Company LLC from $50.00 to $44.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, StockNews.com \u2026",
            "url": "https://www.etfdailynews.com/2023/11/12/surmodics-nasdaqsrdx-price-target-cut-to-44-00-by-analysts-at-needham-company-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/surmodics-inc-logo.png?v=20221209141149&w=240&h=240&zc=2",
            "publishedAt": "2023-11-12T07:48:50Z",
            "content": "Surmodics (NASDAQ:SRDX \u2013 Free Report) had its price objective reduced by Needham &amp; Company LLC from $50.00 to $44.00 in a research note published on Wednesday morning, Benzinga reports. They curr\u2026 [+2752 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium",
            "description": "(marketscreener.com) \nDr. Peter A. Schneider to share trial results during a Nov. 15 session\n\nhttps://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodics-Announces-TRANSCEND-Trial-36-Month-Data-to-be-Presented-at-50th-Annual-VEITH-Symposium-\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodics-Announces-TRANSCEND-Trial-36-Month-Data-to-be-Presented-at-50th-Annual-VEITH-Symposium-45259611/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-07T12:32:02Z",
            "content": "Dr. Peter A. Schneider to share trial results during a Nov. 15 session\r\nSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ind\u2026 [+5494 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium",
            "description": "(marketscreener.com) \nSundance\u2122 Sirolimus Drug-Coated Balloon exhibits excellent safety profile\n\n\nPrimary patency maintained at 24 months in 71.4% of per protocol analysis population\n\nhttps://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodi\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SURMODICS-INC-10935/news/Surmodics-Announces-24-Month-Data-from-the-SWING-Trial-Presented-at-VEITHsymposium-45373041/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-16T12:31:02Z",
            "content": "Sundance Sirolimus Drug-Coated Balloon exhibits excellent safety profile\r\nPrimary patency maintained at 24 months in 71.4% of per protocol analysis population\r\nSurmodics, Inc. (NASDAQ:SRDX), a leadin\u2026 [+6064 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Ibtimes.com.au"
            },
            "author": null,
            "title": "Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15",
            "description": "35-subject SWING Trial evaluates the safety, performance of Surmodics\u2019 Sundance\u2122 Sirolimus Drug-Coated Balloon",
            "url": "https://www.ibtimes.com.au/press-release/20231108/surmodics-announces-swing-trial-24-month-data-to-be-presented-at-veith-symposium-on-november-15",
            "urlToImage": "",
            "publishedAt": "2023-11-07T14:12:10Z",
            "content": "35-subject SWING Trial evaluates the safety, performance of Surmodics\u2019 Sundance\u2122 Sirolimus Drug-Coated Balloon\r\nUpdated safety and performance data for the SWING trial 24-month data will be shared\r\nE\u2026 [+4957 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Ibtimes.com.au"
            },
            "author": null,
            "title": "Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium",
            "description": "Sundance\u2122 Sirolimus Drug-Coated Balloon exhibits excellent safety profile",
            "url": "https://www.ibtimes.com.au/press-release/20231117/surmodics-announces-24-month-data-from-the-swing-trial-presented-at-veithsymposium",
            "urlToImage": "",
            "publishedAt": "2023-11-16T13:08:33Z",
            "content": "Sundance\u2122 Sirolimus Drug-Coated Balloon exhibits excellent safety profile\r\nPrimary patency maintained at 24 months in 71.4% of per protocol analysis population\r\nEDEN PRAIRIE, Minn.--(BUSINESS WIRE)--\u2026 [+6107 chars]"
        }
    ]
}